Skip to main content
. Author manuscript; available in PMC: 2014 Sep 24.
Published in final edited form as: Nat Commun. 2014 Mar 24;5:3469. doi: 10.1038/ncomms4469

Figure 3. SETD2 Mutations in de novo ALL.

Figure 3

A) Amplification and Illumina sequencing of coding exons of SETD2 and other frequently mutated genes in an validation cohort of 125 de novo ALL patients identified 20 additional SETD2 mutations in 15 patients (12%). Relapse status is noted above. Final risk category and molecular subtypes listed below. MLL: MLL rearranged, HYPO: Hypodiploidy, iAMP21: intrachromosomal amplification of chromosome 21, HYPER: Hyperdiploidy. B) Schematic of somatic SETD2 mutations found in ALL patients.

HHS Vulnerability Disclosure